Real World Study
7
4
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
Validation of RCC Predicting Model With Emulated-target Trial
A Real World Study of Respiratory Critical Disease.
Dementia and Kidney Disease: Epidemiological Approaches to Risk Factors and Treatment Strategies
The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Registry Study of Medical Therapy in Patients With Angina Pectoris(GREAT)